Atrium Therapeutics (RNA) CSO Younis Withholds 11,216 Shares for Taxes

What Happened

• Younis Husam, Chief Scientific Officer of Atrium Therapeutics (RNA), had 11,216 shares withheld by the company to satisfy tax withholding obligations tied to the vesting of restricted stock units. The shares were valued at $8.95 each, totaling approximately $100,383, on 2026-09-18. This is a routine tax-withholding disposition, not an open-market sale.

Key Details

• Transaction date and price: 2026-09-18 — 11,216 shares withheld at $8.95 each (total ~$100,383).
• Type of transaction: Tax withholding related to RSU vesting (Footnote F1 clarifies issuer withheld shares to satisfy tax obligations).
• Shares owned after transaction: Not specified in the provided Form 4 excerpt.
• Filing date and timeliness: Form 4 filed 2026-09-22; timing appears timely for a report of a 9/18 transaction (filed within required reporting window).

Context

• This was a cashless/tax-withholding disposition of vested restricted stock units — a common administrative action that reduces share count but is not a market sale indicating directional trading intent.
• Such withholdings are routine and generally should not be interpreted as a signal about the insider’s view of the company’s prospects.